Xoma Royalty buys Turnstone: what do royalty deals offer?
XOMA Royalty’s acquisition of Turnstone Biologics highlights how royalty deals can revive biopharma companies and drive industry innovation.| Labiotech.eu
XOMA Royalty’s acquisition of Turnstone Biologics highlights how royalty deals can revive biopharma companies and drive industry innovation.| Labiotech.eu
From groundbreaking immunotherapies to AI diagnostics and new vaccines, explore the innovations shaping the future of cancer treatment.| Labiotech.eu
The companies Mirador Therapeutics, Alumis, and Sionna Therapeutics bagged the biggest private biotech investments in March 2024.| Labiotech.eu
